French Biotech Cellectis Shares Surge Amid Clinical Advances
Cellectis, a French biotechnology company, has seen a significant increase in its share price, driven by promising clinical trial results and strong technical indicators.
Stock Performance Overview
The stock of French biotech Cellectis closed on Wednesday, December 10 at 4.26 euros, up 6.1% from the previous session where it was quoted at 4.02 euros. This performance occurred in a context of moderate volumes with 0.52% of the capital traded. Over the week, the stock has shown an increase of 4.54%, confirming a positive short-term dynamic. Moreover, the stock is on a remarkable long-term trend with a jump of 71.77% over three months and a surge of 131.5% over twelve months. This outperformance places the stock among the most dynamic biotechnological values on the Paris stock exchange, reflecting growing investor interest in the company's advances in allogeneic CAR-T therapies.
Promising Clinical Trial Results
The company announced during the 67th Annual Congress of the American Society of Hematology in Orlando the presentation of encouraging data from the phase 1 NATHALI-01 clinical trial evaluating the candidate product eti-cel, with an overall response rate of 88% and a complete response rate of 63% at the current dose level. Eti-cel is the first allogeneic double CAR product candidate simultaneously targeting CD20 and CD22, developed for patients with relapsed or refractory non-Hodgkin lymphoma after at least two lines of treatment. These preliminary results are an important catalyst for the stock and justify the observed session gains. The company will start recruiting for the IL-2 cohort in the first quarter of 2026, thus expanding its clinical development prospects. These announcements reinforce the biotech's strategy in the field of allogeneic immunotherapy and strengthen the visibility of its pipeline.
Technical Indicators and Market Position
The share price is significantly above its main moving averages, with a 50-day moving average at 3.55 euros and a 200-day moving average at 2.18 euros, which are respectively 20% and 95.4% below the closing level. This configuration indicates a well-established medium and long-term bullish trend. The RSI is at 53, in a neutral zone that leaves room before reaching an overbought level, suggesting that the movement could continue. However, the MACD histogram shows a negative value of -0.05, with the MACD line at 0.21 slightly below its signal line at 0.26, indicating a possible short-term consolidation phase. The Bollinger Bands frame the stock between 3.25 euros and 4.80 euros, placing the current price in the upper part of the technical corridor. The one-month volatility is set at 23.67%, reflecting the wide fluctuations characteristic of biotechnological values in advanced clinical phases. The stock is slightly below its major resistance threshold at 4.55 euros, a level that could be tested soon if the upward momentum continues.
